Navigation Links
Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
Date:10/20/2010

CHADDS FORD, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its third quarter 2010 financial results on November 1, 2010 and will host a conference call and webcast at 10:00 a.m. ET that day to discuss these results.  

David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer and Blaine Davis, vice president, corporate affairs will host the call.

Investors and other interested parties may call 866-788-0543 (domestic) or 857-350-1681 (international) and enter passcode 81013739.  Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from November 1 at 1:00 p.m. ET until 12:00 a.m. ET on November 9 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 88788586.

A simultaneous webcast of the call may be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 12:00 a.m. ET on November 9.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiary HealthTronics, Inc., please visit www.endo.com.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
2. MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
3. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
4. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
5. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
7. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
8. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
9. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
10. Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
11. ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: ... Financial Officer, will present at the Deutsche Bank 41st Annual ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... the Presentations and Webcasts section of Shire,s Investor website at ... be available on this same website for approximately 90 days. ...
(Date:4/27/2016)... 2016 Global  urinalysis market ... by 2022, according to a new report by ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation ... and accuracy delivered by the new generation urinalysis ... urinalysis instruments and consumables. For instance, the automatic ...
(Date:4/26/2016)... April 26, 2016 Diplomat Pharmacy, Inc. (NYSE: ... Jennifer Hagerman , Pharm D., to Vice President of ... at Diplomat, Hagerman will continue to lead and oversee ... delivers custom education and training to Diplomat employees and ... industry. Diplomat University also houses the quality assurance department, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... 29, 2016 , ... The Wharton School of the ... Prize of the 2016 Wharton Business Plan Competition —as well as the ... and the Committee Award for Most ‘Wow Factor,’ making them the first team ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent ... cancer deaths. More than 10,000 people are expected to die of melanoma this year. The ... the one of the most commonly diagnosed cancers in young women. A recent breakthrough in ...
(Date:4/29/2016)... ... ... City based oral and maxillofacial surgeon Dr. Majid Jamali is an expert in ... apnea. Dr. Jamali is proud to offer this permanent solution to patients who suffer from ... bones. This surgery is performed to correct the alignment of the jaw. It is beneficial ...
Breaking Medicine News(10 mins):